{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T11:39:42Z","timestamp":1763811582255,"version":"3.37.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100018560","name":"Shenzen Municipal and Hong Kong Joint Innovation Project","doi-asserted-by":"crossref","award":["SGDX20201103095603009"],"award-info":[{"award-number":["SGDX20201103095603009"]}],"id":[{"id":"10.13039\/501100018560","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Inf Sci Syst"],"DOI":"10.1007\/s13755-024-00310-w","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T02:26:53Z","timestamp":1731292013000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Machine-learning-based prediction of cardiovascular events for hyperlipidemia population with lipid variability and remnant cholesterol as biomarkers"],"prefix":"10.1007","volume":"12","author":[{"given":"Zhenzhen","family":"Du","sequence":"first","affiliation":[]},{"given":"Shuang","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Ouzhou","family":"Yang","sequence":"additional","affiliation":[]},{"given":"Juan","family":"He","sequence":"additional","affiliation":[]},{"given":"Yujie","family":"Yang","sequence":"additional","affiliation":[]},{"given":"Jing","family":"Zheng","sequence":"additional","affiliation":[]},{"given":"Honglei","family":"Zhao","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8797-4243","authenticated-orcid":false,"given":"Yunpeng","family":"Cai","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"310_CR1","first-page":"209","volume":"34","author":"SS Hu","year":"2019","unstructured":"Hu SS, Gao RL, Liu LS, et al. Summary of the 2018 report on cardiovascular diseases in China. Chin Circ J. 2019;34:209\u201320.","journal-title":"Chin Circ J"},{"issue":"9493","key":"310_CR2","first-page":"1267","volume":"66","author":"ES Unit","year":"2005","unstructured":"ES Unit. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet. 2005;66(9493):1267\u201378.","journal-title":"Lancet"},{"key":"310_CR3","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1161\/CIRCULATIONAHA.108.816694","volume":"119","author":"MJ Pencina","year":"2009","unstructured":"Pencina MJ, D\u2019Agostino RB Sr, Larson MG, et al. Predicting the 30-year risk of cardiovascular disease: the Framingham heart study. Circulation. 2009;119:3078\u201384.","journal-title":"Circulation"},{"key":"310_CR4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrcardio.2015.28","volume":"12","author":"D Zhao","year":"2015","unstructured":"Zhao D, Liu J, Xie W, et al. Cardiovascular risk assessment: a global perspective. Nat Rev Cardiol. 2015;12:301\u201311.","journal-title":"Nat Rev Cardiol"},{"key":"310_CR5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jacc.2003.08.061","volume":"43","author":"AM Gotto Jr","year":"2004","unstructured":"Gotto AM Jr, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol. 2004;43:717\u201324.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"310_CR6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrcardio.2010.222","volume":"8","author":"M Navab","year":"2011","unstructured":"Navab M, Reddy ST, van Lenten BJ, et al. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8(4):222\u201332.","journal-title":"Nat Rev Cardiol"},{"key":"310_CR7","first-page":"2551","volume":"27","author":"C Donald","year":"2018","unstructured":"Donald C, Nicholls SJ, Julie SJ, et al. Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes. Eur Heart J. 2018;27:2551.","journal-title":"Eur Heart J"},{"issue":"19","key":"310_CR8","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.jacc.2016.08.038","volume":"68","author":"DT Ko","year":"2016","unstructured":"Ko DT, Alter DA, Guo H, et al. High-density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions: the CANHEART study. J Am Coll Cardiol. 2016;68(19):2073\u201383.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"310_CR9","volume":"8","author":"HJ Lee","year":"2019","unstructured":"Lee HJ, Lee SR, Choi EK, et al. Low lipid levels and high variability are associated with the risk of new-onset atrial fibrillation. J Am Heart Assoc. 2019;8(23): e012771.","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"310_CR10","volume":"9","author":"BH Han","year":"2020","unstructured":"Han BH, Han K, Yoon KH, et al. Impact of mean and variability of high-density lipoprotein\u2013cholesterol on the risk of myocardial infarction, stroke, and mortality in the general population. J Am Heart Assoc. 2020;9(7): e015493.","journal-title":"J Am Heart Assoc"},{"issue":"23","key":"310_CR11","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1161\/CIRCULATIONAHA.118.034978","volume":"138","author":"MK Kim","year":"2018","unstructured":"Kim MK, Han K, Park YM, et al. Associations of variability in blood pressure, glucose and cholesterol concentrations, and body mass index with mortality and cardiovascular outcomes in the general population. Circulation. 2018;138(23):2627\u201337.","journal-title":"Circulation"},{"issue":"15","key":"310_CR12","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jacc.2015.02.017","volume":"65","author":"S Bangalore","year":"2015","unstructured":"Bangalore S, Breazna A, DeMicco DA, et al. Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial. J Am Coll Cardiol. 2015;65(15):1539\u201348.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"310_CR13","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425\u201335.","journal-title":"N Engl J Med"},{"key":"310_CR14","first-page":"CD004816","volume":"1","author":"F Taylor","year":"2013","unstructured":"Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9435","key":"310_CR15","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet. 2004;364(9435):685\u201396.","journal-title":"Lancet"},{"issue":"5","key":"310_CR16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2337\/dc15-1760","volume":"39","author":"M Gori","year":"2016","unstructured":"Gori M, Gupta DK, Claggett B, et al. Natriuretic peptide and high-sensitivity troponin for cardiovascular risk prediction in diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2016;39(5):677.","journal-title":"Diabetes Care"},{"issue":"5","key":"310_CR17","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00125-017-4442-9","volume":"61","author":"KN Bachmann","year":"2018","unstructured":"Bachmann KN, Wang TJ. Biomarkers of cardiovascular disease: contributions to risk prediction in individuals with diabetes. Diabetologia. 2018;61(5):987\u201395.","journal-title":"Diabetologia"},{"issue":"6","key":"310_CR18","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/dom.13238","volume":"20","author":"ACB Thuesen","year":"2018","unstructured":"Thuesen ACB, Vaag A. Perspectives on diabetes mortality as the result of residual confounding and reverse causality by common disease. Diabetes Obes Metab. 2018;20(6):1342\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"310_CR19","volume":"8","author":"Z Du","year":"2020","unstructured":"Du Z, Yang Y, Zheng J, et al. Accurate prediction of coronary heart disease for patients with hypertension from electronic health records with big data and machine-learning methods: model development and performance evaluation. JMIR Med Inform. 2020;8(7): e17257.","journal-title":"JMIR Med Inform"},{"issue":"1","key":"310_CR20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.gheart.2012.12.004","volume":"8","author":"SS Franklin","year":"2013","unstructured":"Franklin SS, Wong ND. Hypertension and cardiovascular disease: contributions of the Framingham heart study. Glob Heart. 2013;8(1):49\u201357.","journal-title":"Glob Heart"},{"issue":"6","key":"310_CR21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamacardio.2017.0363","volume":"2","author":"J Chen","year":"2017","unstructured":"Chen J, Budoff MJ, Reilly MP, et al. Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease. JAMA Cardiol. 2017;2(6):635\u201343.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"310_CR22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1681\/ASN.2014020173","volume":"26","author":"K Matsushita","year":"2015","unstructured":"Matsushita K, Sang Y, Ballew SH, et al. Subclinical atherosclerosis measures for cardiovascular prediction in CKD. J Am Soc Nephrol. 2015;26(2):439\u201347.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"310_CR23","first-page":"1","volume":"15","author":"JR Zhu","year":"2018","unstructured":"Zhu JR, Gao RL, Zhao SP, et al. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2018;15(1):1\u201329.","journal-title":"J Geriatr Cardiol"},{"key":"310_CR24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","volume":"290","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2020;290:140\u2013205.","journal-title":"Atherosclerosis"},{"issue":"18","key":"310_CR25","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","volume":"97","author":"PWF Wilson","year":"1998","unstructured":"Wilson PWF, D\u2019Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837\u201347.","journal-title":"Circulation"},{"key":"310_CR26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.phrs.2017.11.003","volume":"129","author":"SE Kjeldsen","year":"2017","unstructured":"Kjeldsen SE. Hypertension and cardiovascular risk: general aspects. Pharmacol Res. 2017;129:95\u20139.","journal-title":"Pharmacol Res"},{"key":"310_CR27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/er.2018-00184","volume":"40","author":"PB Sandesara","year":"2019","unstructured":"Sandesara PB, Virani SS, Fazio S, et al. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev. 2019;40:537\u201357.","journal-title":"Endocr Rev"},{"key":"310_CR28","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.3390\/diagnostics12081965","volume":"12","author":"PC Liao","year":"2022","unstructured":"Liao PC, Chen MS, et al. Integrating health data-driven machine learning algorithms to evaluate risk factors of early stage hypertension at different levels of HDL and LDL cholesterol. Diagnostics. 2022;12:1965.","journal-title":"Diagnostics"},{"key":"310_CR29","volume":"151","author":"H Huang","year":"2022","unstructured":"Huang H, Ren YB, et al. Using a machine learning-based risk prediction model to analyze the coronary artery calcification score and predict coronary heart disease and risk assessment. Comput Biol Med. 2022;151: 106297.","journal-title":"Comput Biol Med"},{"key":"310_CR30","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","volume":"76","author":"MJ Domanski","year":"2020","unstructured":"Domanski MJ, Tian X, Wu CO, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol. 2020;76:1507\u201316.","journal-title":"J Am Coll Cardiol"},{"key":"310_CR31","doi-asserted-by":"crossref","DOI":"10.1002\/9781118548387","volume-title":"Applied logistic regression","author":"DW Hosmer","year":"2013","unstructured":"Hosmer DW, Lemeshow S, Sturdivant RX. Applied logistic regression. 3rd ed. Hoboken: Wiley; 2013.","edition":"3"},{"key":"310_CR32","first-page":"273","volume":"20","author":"C Cortes","year":"1995","unstructured":"Cortes C, Vapnik V. Support-vector networks. Mach Learn. 1995;20:273\u201397.","journal-title":"Mach Learn"},{"key":"310_CR33","first-page":"3146","volume":"30","author":"G Ke","year":"2017","unstructured":"Ke G, Meng Q, Finley T, et al. LightGBM: a highly efficient gradient boosting decision tree. Adv Neural Inf Process Syst. 2017;30:3146\u201354.","journal-title":"Adv Neural Inf Process Syst"},{"key":"310_CR34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bdr.2021.100234","volume":"25","author":"Y Yang","year":"2021","unstructured":"Yang Y, Li Y, Chen R, et al. Risk prediction of renal failure for chronic disease population based on electronic health record big data. Big Data Res. 2021;25: 100234.","journal-title":"Big Data Res"},{"issue":"11","key":"310_CR35","doi-asserted-by":"crossref","DOI":"10.2196\/30277","volume":"9","author":"Y Yang","year":"2021","unstructured":"Yang Y, Zheng J, Du Z, et al. Accurate prediction of stroke for hypertensive patients based on medical big data and machine learning algorithms: retrospective study. JMIR Med Inform. 2021;9(11): e30277.","journal-title":"JMIR Med Inform"},{"issue":"7","key":"310_CR36","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jclinepi.2009.12.008","volume":"63","author":"KJM Janssen","year":"2010","unstructured":"Janssen KJM, Donders ART, Harrell FE Jr, et al. Missing covariate data in medical research: to impute is better than to ignore. J Clin Epidemiol. 2010;63(7):721\u20137.","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"310_CR37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/heartjnl-2011-301246","volume":"98","author":"KGM Moons","year":"2012","unstructured":"Moons KGM, Kengne AP, Woodward M, et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio) marker. Heart. 2012;98(9):683\u201390.","journal-title":"Heart"},{"key":"310_CR38","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2012","unstructured":"Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: machine learning in Python. J Mach Learn Res. 2012;12:2825\u201330.","journal-title":"J Mach Learn Res"},{"unstructured":"Buitinck L, Louppe G, Blondel M, Pedregosa F, Mueller A, Grisel O, et al. API design for machine learning software experiences from the Scikit-learn project. arXiv preprint 2013. Sep:1309.0238.","key":"310_CR39"},{"key":"310_CR40","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCULATIONAHA.119.041149","volume":"140","author":"C Welsh","year":"2019","unstructured":"Welsh C, Celis-Morales CA, BrownClaire R, et al. comparison of conventional lipoprotein tests and apolipoproteins in the prediction of cardiovascular disease. Circulation. 2019;140:542\u201352.","journal-title":"Circulation"},{"key":"310_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.g4356","volume":"349","author":"S Rabar","year":"2014","unstructured":"Rabar S, Harker M, Flynn N, et al. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ. 2014;349:1\u20136.","journal-title":"BMJ"},{"issue":"3","key":"310_CR42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034226","volume":"10","author":"L Feng","year":"2020","unstructured":"Feng L, Nian SY, Tong ZW, et al. Age-related trends in lipid levels: a large-scale cross-sectional study of the general Chinese population. BMJ Open. 2020;10(3): e034226.","journal-title":"BMJ Open"},{"issue":"19","key":"310_CR43","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1161\/CIRCULATIONAHA.118.037885","volume":"139","author":"N Sattar","year":"2019","unstructured":"Sattar N, Rawshani A, Franz\u00e9n S, et al. Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks. Circulation. 2019;139(19):2228\u20132223.","journal-title":"Circulation"},{"issue":"2","key":"310_CR44","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/ndt\/gfab068","volume":"37","author":"RW Horace","year":"2022","unstructured":"Horace RW, Roberts M, Shireman TI, et al. Remnant cholesterol is prospectively associated with cardiovascular disease events and all-cause mortality in kidney transplant recipients: the FAVORIT study. Nephrol Dial Transplant. 2022;37(2):382\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"310_CR45","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12933-020-01076-7","volume":"19","author":"YX Cao","year":"2020","unstructured":"Cao YX, Zhang HW, Jin JL, et al. The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes. Cardiovasc Diabetol. 2020;19(1):104.","journal-title":"Cardiovasc Diabetol"},{"key":"310_CR46","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MOL.0000000000000330","volume":"27","author":"J Boren","year":"2017","unstructured":"Boren J, Williams KJ. The central role of arterial retention of cholesterol rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol. 2017;27:473\u201383.","journal-title":"Curr Opin Lipidol"},{"key":"310_CR47","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","volume":"128","author":"A Varbo","year":"2018","unstructured":"Varbo A, Benn M, Tybj\u00e6rg-Hansen A. Elevated remnant cholesterol causes both low grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2018;128:1298\u2013309.","journal-title":"Circulation"},{"key":"310_CR48","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","volume":"34","author":"AB J\u00f8rgensen","year":"2013","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, West AS, et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013;34:1826\u201333.","journal-title":"Eur Heart J"},{"issue":"42","key":"310_CR49","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1093\/eurheartj\/ehab432","volume":"42","author":"R Quispe","year":"2021","unstructured":"Quispe R, Martin SS, Michos ED, et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur Heart J. 2021;42(42):4324\u201332.","journal-title":"Eur Heart J"},{"issue":"7810","key":"310_CR50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-020-2338-1","volume":"582","author":"NCD-RisC","year":"2020","unstructured":"NCD-RisC. Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020;582(7810):73\u20137.","journal-title":"Nature"},{"issue":"10","key":"310_CR51","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41569-021-00541-4","volume":"18","author":"A Pirillo","year":"2021","unstructured":"Pirillo A, Casula M, Olmastroni E, et al. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;18(10):689\u2013700.","journal-title":"Nat Rev Cardiol"},{"issue":"21","key":"310_CR52","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.3390\/jcm11216377","volume":"11","author":"T Liu","year":"2022","unstructured":"Liu T, Zhao D, Qi Y. Global trends in the epidemiology and management of dyslipidemia. J Clin Med. 2022;11(21):6377.","journal-title":"J Clin Med"},{"key":"310_CR53","doi-asserted-by":"crossref","first-page":"e069116","DOI":"10.1136\/bmj-2021-069116","volume":"377","author":"SU Khan","year":"2022","unstructured":"Khan SU, Yedlapati SH, Lone AN, et al. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. BMJ. 2022;377:e069116.","journal-title":"BMJ"},{"doi-asserted-by":"crossref","unstructured":"Chen T, Guestrin C. XGBoost: a scalable tree boosting system. In: Proceedings of the 22nd ACM SIGKDD international conference on knowledge discovery and data mining, 2016, pp 785\u201394.","key":"310_CR54","DOI":"10.1145\/2939672.2939785"}],"container-title":["Health Information Science and Systems"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13755-024-00310-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13755-024-00310-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13755-024-00310-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T08:32:47Z","timestamp":1733214767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13755-024-00310-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["310"],"URL":"https:\/\/doi.org\/10.1007\/s13755-024-00310-w","relation":{},"ISSN":["2047-2501"],"issn-type":[{"type":"electronic","value":"2047-2501"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"22 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest regarding the publication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Shenzhen Institutes of Advanced Technology Institutional Review Board (No. SIAT-IRB-151115-H0084).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"51"}}